Matrix effect and cross-reactivity of select amphetamine-type substances, designer analogues, and putrefactive amines using the bio-quant direct ELISA presumptive assays for amphetamine and methamphetamine

Journal of Analytical Toxicology

Volumn 31, Issue 4, 2007, Pages 208-213

  Apollonio, Luigino G ^a   Whittall, Ian R ^b   Pianca, Dennis J ^b   Kyd, Jennelle M ^a   Maher, William A ^a  

^a UNIVERSITY OF CANBERRA   (Australia)

^b ACT Government Analytical Laboratory   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 BROMO 2,5 DIMETHOXYPHENETHYLAMINE; 4 METHOXYAMPHETAMINE; 4 METHYLTHIOAMPHETAMINE; AMINE; AMPHETAMINE; EPHEDRINE; METHAMPHETAMINE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; PHENETHYLAMINE; PHENETHYLAMINE DERIVATIVE; PHENTERMINE; PSEUDOEPHEDRINE; PUTRESCINE; TRYPTAMINE; TYRAMINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD ANALYSIS; BODY FLUID; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; SALIVA ANALYSIS; SCREENING; SENSITIVITY ANALYSIS; URINALYSIS;

EID: 34248210037     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/31.4.208     Document Type: Article

References (29)

1. J. Hsu, C. Liu, C.P. Hsu, W-I. Tsay, J-H. Li, D-L. Lin, and R.H. Liu. Performance characteristics of selected immunoassays for preliminary test of 3,4-methylenedioxymethamphetamine, methamphetamine, and related drugs in urine specimens. J. Anal. Toxicol. 27: 471-478 (2003).
2. H. Zhao, R. Brenneisen, A. Scholar, A.J. McNally, M.A. Elsohly, T.P. Murphy, and S.J. Salamone. Profiles of urine samples taken from ecstasy users at rave parties: analysis by immunoassays, HPLC, and GC-MS. J. Anal. Toxicol. 25: 258-269 (2001).
3. J. D'Nicuola, R. Jones, B. Levine, and M.L. Smith. Evaluation of six commercial amphetamine and methamphetamine immunoassays for cross-reactivity to phenylpropanolamine and ephedrine in urine. J. Anal. Toxicol. 16: 211-213 (1992).
4. P.R. Stout, K.L. Klette, and R. Wiegand. Comparison and evaluation of DRI® methamphetamine, DRI® ecstasy, Abuscreen® ONLINE amphetamine, and a modified Abuscreen® ONLINE amphetamine screening immunoassays for the detection of amphetamine (AMP), methamphetamine (MTH), 3,4- methylenedioxyamphetamine (MDA), and 3,4-methylenedioxmethamphetamine (MDMA) in urine. J. Anal. Toxicol. 27: 265-269 (2003).
5. I.B. Collison, V.R. Spiehler, S. Guluzian, and P.R. Sedgwick. Setting cutoff concentrations for immunoassay screening of post-mortem blood. J. Forensic Sci. 43: 390-394 (1998).
6. V.R. Spiehler, I.B. Collison, P.R. Sedgwick, S.L. Perez, S.D. Le, and D.A. Farnin. Validation of an automated microplate enzyme immunoassay for screening of post-mortem blood for drugs of abuse. J. Anal. Toxicol. 22: 573-579 (1998).
7. D. Felscher and K. Schulz. Screening of amphetamine/methamphetamine and their derivatives in urine using FPIA and Triage ™8 and the scope and limits of a subsequent identification by means of the REMEDi™ HS system. J. Forensic Sci. 45: 1327-1331 (2000).
8. C. Marson, S. Schneider, F. Meys, and R. Wennig. Structural elucidation of an uncommon phenylethylamine analogue in urine responsible for discordant amphetamine immunoassay results. J. Anal. Toxicol. 24: 17-21 (2000).
9. J.T. Cody and R. Schwarzhoff. Fluorescence polarization immunoassay detection of amphetamine, methamphetamine, and illicit amphetamine analogues. J. Anal. Toxicol. 17: 26-30 (1993).
10. R. Loor, C. Lingenfelter, P.P. Wason, K. Tang, and D. Davoudzadeh. Multiplex assay of amphetamine, methamphetamine, and ecstasy drug using CEDIA® technology. J. Anal. Toxicol. 26: 267-273 (2002).
11. M. Huang, Y. Dai, C. Lee, C. Liu, W. Tsay, and J. Li. Performance characteristics of DRI, CEDIA, and REMEDi systems for preliminary tests of amphetamines and opiates in human urine. J. Anal. Toxicol. 30: 61-64 (2006).
12. M.L. Smith. Immunoassay. In Principles of Forensic Toxicology, 2nd ed., B. Levine, Ed. AACC Press, Washington, D.C., 2003, pp 117-137.
13. J.R. Crowther. The ELISA Guidebook, vol. 149. Humana Press, Totowa, NJ, 2001, p vii.
14. T. Kupiec, L. DeCicco, V. Spiehler, G. Sneed, and P. Kemp. Choice of an ELISA assay for screening postmortem blood for amphetamine and/or methamphetamine. J. Anal. Toxicol. 26: 513-518 (2002).
15. M. Laloup, G. Tilman, V. Maes, G. De Boeck, P. Wallemacq, J. Ramaekers, and N. Samyn. Validation of an ELISA-based screening assay for the detection of amphetamine, MDMA, and MDA in blood and oral fluid. Forensic Sci. Int. 153: 29-37 (2005).
16. G. Cooper, L. Wilson, C. Reid, C. Hand, and V. Spiehler. Validation of the Cozart® amphetamine microplate EIA for the analysis of amphetamines in oral fluid. Forensic Sci. Int. 159: 104-112 (2006).
17. S. Kerrigan and W.H. Phillips, Jr. Comparison of ELISAs for opiates, methamphetamine, cocaine metabolite, benzodiazepines, phencyclidine, and cannabinoids in whole blood and urine. Clin. Chem. 47: 540-547 (2001).
18. H.R.M. Far, F. Torabi, B. Danielsson, and M. Khayyami. ELISA on a microchip with a photodiode for detection of amphetamine in plasma and urine. J. Anal. Toxicol. 29: 790-793 (2005).
19. J.S. Oliver, H. Smith, and D.J. Williams. The detection, identification, and measurement of indole, tryptamine, and 2-phenethylamine in putrefying human tissue. Forensic Sci. 9: 195-203 (1977).
20. J.S. Oliver and H. Smith. The interference of putrefactive bases in the analysis of biological materials for drugs. J. Forensic Sci. Soc. 13: 47-54 (1973).
21. H.M. Stevens. The stability of some drugs and poisons in putrefying human liver tissues. J. Forensic Sci. Soc. 24: 577-589 (1984).
22. H.M. Stevens and P.D. Evans. Identification tests for bases formed during the putrefaction of visceral material. Acta Pharmacol. Toxicol. 32: 525-552 (1973).
23. B. Kaempe. Interfering compounds and artefacts in the identification of drugs in autopsy material. In Progress in Chemical Toxicology, Vol. 4 . Academic Press, New York, NY, 1969, pp 6-7.
24. B.J. Perrigo and B.P. Joynt. Use of ELISA for the detection of common drugs of abuse in forensic whole blood samples. Can. Soc. Forensic Sci. J. 28: 261-269 (1995).
25. K.A. Moore, C. Werner, R.M. Zannelli, B. Levine, and M.L. Smith. Screening post-mortem blood and tissues for nine cases of drugs of abuse using automated microplate immunoassay. Forensic Sci. Int. 106: 93-102 (1999).
26. J. Eichorst. ?-Phenethylamine causes false-positive amphetamines in post-mortem specimens when tested by Syva EMIT. Forensic Sci. Int. 50: 139-140 (1991).
27. Y. Hino, I. Ojanpera, I. Rasanen, and E. Vuori. Performance of immunoassays in screening for opiates, cannabinoids, and amphetamines in post-mortem blood. Forensic Sci. Int. 131: 148-155 (2003).
28. O.H. Drummer and J. Gerostamoulos. Postmortem drug analysis: analytical and toxicological aspects. Ther. Drug. Monit. 24: 199-209 (2002).
29. J.W.A. Findlay, W.C. Smith, J.W. Lee, G.D. Nordblom, I. Daes, B.S. De Silva, M.N. Khan, and R.R. Bowsher. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21: 1249-1273 (2000).